Overview
Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.
Indication
For the treatment of serious infections caused by susceptible strains microorganisms.
Associated Conditions
- Abscess, Intra-Abdominal
- Animal bite
- Bacterial Infections
- Bacterial Urinary Tract Infections
- Bone and Joint Infections
- Endometritis
- Flu caused by Influenza
- Gynecological Infection
- Intraabdominal Infections
- Lower respiratory tract infection bacterial
- Lung Abscess
- Pelvic Inflammatory Disease (PID)
- Pelvic cellulitis
- Peritonitis
- Pneumonia
- Septicemia
- Skin and Subcutaneous Tissue Bacterial Infections
Research Report
Cefoxitin: A Comprehensive Pharmacological and Clinical Review
1. Introduction to Cefoxitin
1.1. Overview, Classification, and Origin
Cefoxitin is a semi-synthetic, broad-spectrum antibiotic agent intended for parenteral administration, primarily utilized in the management of serious bacterial infections.[1] Within the landscape of antimicrobial agents, Cefoxitin holds a distinct position. It is classified as a cephamycin antibiotic, a subgroup of beta-lactam antibiotics, and is frequently categorized alongside second-generation cephalosporins.[1] This dual classification is not merely academic; it reflects its unique structural attributes and, consequently, its particular spectrum of activity and clinical utility. The "second-generation cephalosporin" grouping generally implies an enhanced spectrum against Gram-negative bacteria compared to first-generation agents, often with some activity against anaerobic bacteria. Cefoxitin aligns with this but its cephamycin nature, specifically the presence of a 7-alpha-methoxy group on its core structure, confers a notable degree of stability against a wide array of bacterial beta-lactamases.[2] This enzymatic stability is a cornerstone of its efficacy against certain challenging pathogens, including many anaerobic organisms, and distinguishes it from many other cephalosporins.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/03/06 | Phase 1 | Active, not recruiting | |||
2024/08/20 | Phase 3 | Recruiting | |||
2020/03/17 | Phase 2 | Recruiting | |||
2017/09/01 | Phase 3 | Completed | |||
2016/12/07 | Not Applicable | UNKNOWN | Hospital de Santa Maria, Portugal | ||
2016/03/09 | Phase 4 | Completed | |||
2015/06/18 | Phase 4 | Terminated | Central Hospital, Nancy, France | ||
2013/03/29 | Not Applicable | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.